UBS analyst Ashwani Verma upgraded Royalty Pharma (RPRX) to Buy from Neutral with a price target of $49, up from $38. The company has done a series of attractive royalty deals, which boosts its growth profile “meaningfully,” the analyst tells investors in a research note. The firm sees a “catalyst-rich” 2026 for Royalty that can drive “significant stock upside on upcoming de-risking events.” The company’s growth profile is attractive on both an absolute and relative basis versus a number of large-cap pharma names that are facing material loss of exclusivities, contends UBS.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Royalty Pharma price target raised to $50 from $48 at Citi
- Royalty Pharma provides update on business performance
- Royalty Pharma, Teva enter agreement to accelerate development of TEV-‘408
- Royalty Pharma board increases quarterly dividend 6.8% to 23.5c per share
- Royalty Pharma acquires reaming royalty interest in Evrysdi for $240M upfront